1. Home
  2. UBX vs CXAI Comparison

UBX vs CXAI Comparison

Compare UBX & CXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UBX
  • CXAI
  • Stock Information
  • Founded
  • UBX 2009
  • CXAI N/A
  • Country
  • UBX United States
  • CXAI United States
  • Employees
  • UBX N/A
  • CXAI N/A
  • Industry
  • UBX Biotechnology: Pharmaceutical Preparations
  • CXAI EDP Services
  • Sector
  • UBX Health Care
  • CXAI Technology
  • Exchange
  • UBX Nasdaq
  • CXAI Nasdaq
  • Market Cap
  • UBX 24.6M
  • CXAI 26.7M
  • IPO Year
  • UBX 2018
  • CXAI N/A
  • Fundamental
  • Price
  • UBX $1.26
  • CXAI $1.43
  • Analyst Decision
  • UBX Strong Buy
  • CXAI
  • Analyst Count
  • UBX 3
  • CXAI 0
  • Target Price
  • UBX $9.00
  • CXAI N/A
  • AVG Volume (30 Days)
  • UBX 70.7K
  • CXAI 496.2K
  • Earning Date
  • UBX 11-04-2024
  • CXAI 11-12-2024
  • Dividend Yield
  • UBX N/A
  • CXAI N/A
  • EPS Growth
  • UBX N/A
  • CXAI N/A
  • EPS
  • UBX N/A
  • CXAI N/A
  • Revenue
  • UBX N/A
  • CXAI $7,200,000.00
  • Revenue This Year
  • UBX N/A
  • CXAI $8.01
  • Revenue Next Year
  • UBX N/A
  • CXAI $92.31
  • P/E Ratio
  • UBX N/A
  • CXAI N/A
  • Revenue Growth
  • UBX N/A
  • CXAI N/A
  • 52 Week Low
  • UBX $1.11
  • CXAI $1.03
  • 52 Week High
  • UBX $2.26
  • CXAI $7.07
  • Technical
  • Relative Strength Index (RSI)
  • UBX 47.73
  • CXAI 43.88
  • Support Level
  • UBX $1.11
  • CXAI $1.35
  • Resistance Level
  • UBX $1.37
  • CXAI $2.02
  • Average True Range (ATR)
  • UBX 0.08
  • CXAI 0.13
  • MACD
  • UBX 0.00
  • CXAI 0.02
  • Stochastic Oscillator
  • UBX 69.49
  • CXAI 16.90

About UBX Unity Biotechnology Inc.

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

About CXAI CXApp Inc.

CXApp Inc is a workplace experience platform for enterprise customers. It is a SaaS product for enterprise organizations, distributing a mobile app to all employees within the organization. It includes a content management system (or CMS) so customers can adjust configurations for their workplace settings autonomously and spontaneously. Its technologies and solutions help enterprise customers deliver a comprehensive business journey in a work 'from anywhere' world for employees, partners, customers, and visitors. CXApp offers native mapping, analytics, on-device positioning (or ODP), and application technologies that bring people together.

Share on Social Networks: